[1]
|
Savi, P., Pereillo, J.M., Uzabiaga, M.F., Combalbert, J., Picard, C., Maffrand, J.P., et al. (2000) Identification and biological activity of the active metabolite of clopidogrel. Journal of Thrombosis and Haemostasis, 84, 891-896.
|
[2]
|
Hulot, J.S., Bura, A., Villard, E., Azizi, M., Remones, V., Goyenvalle, C., et al. (2006) Cytochrome P450 2C19 loss- of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 108, 2244-2247. doi:10.1182/blood-2006-04-013052
|
[3]
|
Sibbing, D., Gebhard, D., Koch, W., Braun, S., Stegherr, J., Morath, T., et al. (2010) Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. Journal of Thrombosis and Haemostasis, 8, 1685-1693.
doi:10.1111/j.1538-7836.2010.03921.x
|
[4]
|
Chan, M.Y., Tan, K., Tan, H.C., Huan, P.T., Li, B., Phua, Q.H., et al. (2012) CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics, 13, 533-542.
doi:10.2217/pgs.12.24
|
[5]
|
Geisler, T., Schaeffeler, E., Dippon, J., Winter, S., Buse, V., Bischofs, C., et al. (2008) CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics, 9, 1251-1259. doi:10.2217/14622416.9.9.1251
|
[6]
|
Hochholzer, W., Trenk, D., Bestehorn, H.P., Fischer, B., Valina, C.M., Ferenc, M., et al. (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. Journal of the American College of Cardiology, 48, 1742-1750.
doi:10.1016/j.jacc.2006.06.065
|
[7]
|
Sibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dorrler, K., et al. (2009)Cytochrome P450 2C19 loss-of- function polymorphism and stent thrombosis following percutaneous coronary intervention. European Heart Journal, 30, 916-922. doi:10.1093/eurheartj/ehp041
|
[8]
|
Collet, J.P., Hulot, J.S., Pena, A., Villard, E., Esteve, J.B., Silvain, J., et al. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet, 373, 309- 317. doi:10.1016/S0140-6736(08)61845-0
|
[9]
|
Shuldiner, A.R., O’Connell, J.R., Bliden, K.P., Gandhi, A., Ryan, K., Horenstein, R.B., et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 302, 849-857. doi:10.1001/jama.2009.1232
|
[10]
|
Mega, J.L., Close, S.L., Wiviott, S.D., Shen, L., Hockett, R.D., Brandt, J.T., et al. (2009)Cytochrome p-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360, 354-362.
doi:10.1056/NEJMoa0809171
|
[11]
|
Zabalza, M., Subirana, I., Sala, J., Lluis-Ganella, C., Lucas, G., Tomas, M., et al. (2012) Meta-analyses of the association between cytochrome CYP2C19 loss- and gain- of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart, 98, 100-108.
doi:10.1136/hrt.2011.227652
|
[12]
|
Mega, J.L., Simon, T., Collet, J.P., Anderson, J.L., Antman, E.M., Bliden, K., et al. (2010)Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA, 304, 1821-1830.
doi:10.1001/jama.2010.1543
|
[13]
|
Sim, S.C., Risinger, C., Dahl, M.L., Aklillu, E., Christensen, M., Bertilsson, L., et al. (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology & Therapeutics, 79, 103-113.
doi:10.1016/j.clpt.2005.10.002
|
[14]
|
Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., et al. (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation, 121, 512-518.
doi:10.1161/CIRCULATIONAHA.109.885194
|
[15]
|
Tiroch, K.A., Sibbing, D., Koch, W., Roosen-Runge, T., Mehilli, J., Schomig, A., et al. (2010) Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. American Heart Journal, 160, 506-512.
doi:10.1016/j.ahj.2010.06.039
|
[16]
|
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: Study design and rationale. American Heart Journal. 2009, 158, 327-344.
|
[17]
|
Chin, C.T., Roe, M.T., Fox, K.A., Prabhakaran, D., Marshall, D.A., Petitjean, H., et al. (2010) Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non- ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syn-dromes (TRI- LOGY ACS) trial. American Heart Journal, 160, 16-22.
|
[18]
|
Scott, S.A., Sangkuhl, K., Gardner, E.E., Stein, C.M., Hulot, J.S., Johnson, J.A., et al. (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clinical Pharmacology & Therapeutics, 90, 328-332. doi:10.1038/clpt.2011.132
|
[19]
|
Thygesen, K., Alpert, J.S. and White, H.D. (2007) Universal definition of myocardial infarction. European Heart Journal, 28, 2525-2538.
|
[20]
|
Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey Jr., D.E., et al. (2007) ACC/ AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the Americ
|
[21]
|
Gurbel, P.A., Tantry, U.S., Shuldiner, A.R. and Kereiakes, D.J. (2010) Genotyping: One piece of the puzzle to personalize antiplatelet therapy. Journal of the American College of Cardiology, 56, 112-116.
doi:10.1016/j.jacc.2010.04.008
|
[22]
|
Gurbel, P.A., Tantry, U.S. and Shuldiner, A.R. (2010) Letter by Gurbel et al. regarding article, “Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement”. Circulation, 122, 478. doi:10.1161/CIRCULATIONAHA.110.943548
|
[23]
|
Harmsze, A.M., van Werkum, J.W., Hackeng, C.M., Ruven, H.J., Kelder, J.C., Bouman, H.J., et al. (2012) The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and Genomics, 22, 169-175.
doi:10.1097/FPC.0b013e32834ff6e3
|
[24]
|
Santos, P.C., Soares, R.A., Santos, D.B., Nascimento, R.M., Coelho, G.L., Nicolau, J.C., et al. (2011) CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Medical Genetics, 12, 13.
doi:10.1186/1471-2350-12-13
|